Landos Biopharma, Inc. (LABP) The latest quarter net income was –$9M, with a YoY change of +13.7%. The company has not reported a profitable quarter in the last 4 quarters. With a market cap data available, MOAT composite score of 28/100 (low competitive position).
Criteria proven by this page:
- GROWTH (40/100, Partial) — growth is present but not consistently above 5% across both metrics
- PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 6-year annual history, the company was profitable in 0 of 6 years — a mixed long-term record
- INCOME (?/100, Fail) — the company is currently operating at a loss
- MOAT (28/100, Fail) — limited competitive moat based on margins and scale
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
